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Breast cancer is considered the most common cancer among women worldwide. In Saudi Arabia, the incidence of breast cancer has been estimated at 21.8%  ADDIN EN.CITE []. According to several studies, only 10% of breast cancer cases have been attributed to an inherited defect in DNA damage recognition and repair genes, BRCA1 and BRCA2  ADDIN EN.CITE []. Thus, the carriers of BRCA1 and BRCA2 mutations are at high risk of developing breast cancer  ADDIN EN.CITE []. However, the genetic predisposition that is limited to BRCA1 and BRCA2 mutations does not explain the etiology of all breast cancer cases. Our body cells are exposed to  a myriad of DNA damaging agents. Unrepaired DNA lesions may end up in the accumulation of deleterious mutations, increasing the genomic instability that potentially increases the chances of cancer development. For instance, Double-Strand Breaks (DSB), the most injurious lesions that result directly from exposure to various endogenous and exogenous agents, play a crucial role in cancer development []. Repairing of DSB occurs either through homologous recombination or non-homologous end-joining pathways  ADDIN EN.CITE [, ].
Homologous recombination, a mechanism that repairs many DNA lesions including DSB, involves strand invasion and uses the complementary intact copy as a template to restore the original sequence at the site of damage. Briefly, BRCA2 binds to RAD51  that translocated to the site of damage, facilitates the formation of helical RAD51–single-stranded DNA (ssDNA) nucleoprotein filaments and search for a homologous DNA template to start strand invasion and repair of the DSBs [, ]. However, excessive or uncontrolled homologous recombination results in deleterious consequences, such as resistance to DNA damaging agents and increased genomic instability that may contribute to carcinogenesis  ADDIN EN.CITE [].
RAD51, a key protein in the homologous recombination, plays a crucial role in genome stability []. Interestingly, several studies have linked the levels of expression, mutations and polymorphisms of  RAD51  recombinases to cancer development  ADDIN EN.CITE []. Increased expression of RAD51 was reported in a large panel of human cancers, particularly in metastatic breast cancer  ADDIN EN.CITE [, ]. Recently, in a clinicopathological study of RAD51 expression in breast cancer, demonstrated that the expression of cytoplasmic RAD51  but not nuclear is associated with high grade, lymph node involvement, and triple-negative breast cancer  ADDIN EN.CITE [].  Furthermore, RAD51 was shown to be downregulated by wild type p53 tumor suppressor gene and since p53 is commonly mutated in breast cancer, there is a tendency for RAD51 to be overexpressed in breast cancer  ADDIN EN.CITE [, ]. RAD51gene polymorphism was reported to increase its promotor activity, and subsequently enhance its expression [].
The polymorphisms of the RAD51 gene, G135C (rs1801320) and G172T (rs1801321) have been studied intensively in breast cancer  ADDIN EN.CITE []. Many researchers have significantly correlated the 135C allele variant with a high risk of breast cancer development  ADDIN EN.CITE [, , ]. Contrariwise, others suggested that G135C polymorphism is associated with a low risk of breast cancer development  ADDIN EN.CITE [, , ]. While, some studies significantly correlated the G172T variant with an increase in the risk of breast cancer  ADDIN EN.CITE [, ] and other cancers such as prostate cancer []. In addition to the polymorphic association with the development of cancers, RAD51 overexpression has been correlated with the resistance to treatment, aggressive phenotype, metastatic behavior, and poor prognosis  ADDIN EN.CITE []. Despite the inconclusive results from many studies, a metanalysis study that included 22,399 subjects showed a strong association between the G135C polymorphism and the development of breast cancer[].
Most of the previous studies investigated the polymorphic variations or RAD51 expression in the clinical specimens. Herein, we aimed at revealing RAD51 gene polymorphisms in the promoter region, G135C and G172T, in correlation with RAD51 expression in sporadic breast cancer.
Methods and Techniques:
Patients and Samples
One hundred and three formalin-fixed paraffin-embedded (FFPE) of sporadic breast cancers were randomly selected and reviewed by two pathologists from the archives of the Pathology Department, King Fahd Hospital of the University. As a control group, sixty blood samples were collected from Saudi females with no history of breast cancer and twenty cases of normal breast tissue.
Immunohistochemistry
Sections from the paraffin blocks of breast cancer tissue were reviewed by pathologists at King Fahd Hospital of the University. Immunohistochemistry procedures performed on 4µm thick paraffin sections with a primary monoclonal antibody for RAD51 (Abcam, ab137323) using Ventana Benchmark according to the manufacturer’s instructions (Ventana Medical Systems Inc., Strasbourg). Ultra-View Universal DAB Detection Kit was used to detect the expression of RAD51, and then sections were counterstained with hematoxylin for the identification of nuclei. Expression and localization of RAD51 were then analyzed. For the evaluation of cytoplasmic expression of RAD51, we determined the staining intensity rated on a scale of 0–3, with 0 for negative;1 for weak; 2 for moderate, and 3 for strong and the percentage of cytoplasmic positive cells (scored as 0, <10%; 1, 10–25%; 2, 25–50%; 3, 50–75%; 4, >75%)  for each sample. An aver all score of ≤3 was defined as negative and a score of >3 as positive. All specimens were evaluated by two pathologists in a blinded manner

DNA isolation
Two sections of 5 µm each from formalin-fixed paraffin-embedded (FFPE) breast cancer tissue was used for DNA extraction. DNA was extracted from breast cancer tissue and the control including normal breast tissue and blood from normal volunteers using QIAamp DNA FFPE Tissue Kit, QIAamp DNA Blood Mini kit (Qiagen, Germany) respectively. DNA was purified using a fully automated system (QIAcube, Qiagen, Germany) with the final volume of 50μl for each sample as per the manufacturer’s instructions. DNA quantity and purity were assessed using Epoch-Bioteck .
PCR amplification
DNA fragment of the 5’-UTR regions of the RAD51 gene was amplified using the primers: Forward Primer: 5'-AGCTGGGAACTGCAACTCAT-3', Reverse Primer: 5'- CGCCTCACACACTCACCTC -3'.  PCR was performed in volume of 25.0 μl containing 12.5 μl Taq PCR Master Mix Kit, 0.2 µM of each primer and 50ng of DNA. The PCR-cycling conditions were optimized as the following: initial denaturation 1 cycle of 3 min at 94◦C; 35cycles of  three steps denaturation for 30 sec at 94◦C, 30 sec annealing at 54◦C, and 30 sec extension at 72◦C; and final extension of 10 min at 72◦C. PCR product was analyzed on the 2% agarose gel, which showed the expected amplicon for all products.
Capillary sequencing
The PCR product was excised and purified from the agarose gel using the QIAquick PCR and Gel clean up kit (Qiagen, Germany) according to the manufacturer’s instructions. With BigDye terminator v3.1 kit (Life Technologies, U.S.A), 10μl volume of Cycle sequencing was prepared as per manufacture’s protocol. PCR product was purified according to BigDyeX Terminator purification kit (Life Technologies, U.S.A) instructions. 10μl of the prepared sample was loaded on 96 well plates and sequenced using ABI 3500 Genetic Analyzer (Life Technologies, USA). All samples were sequenced in both directions. The sequence output was analyzed using applied biosystem software. 
Statistical analysis
Chi-square and Fisher’s exact tests were performed to calculate the p-value and the correlations between the genotypes or allele frequencies and the development of breast cancer or gene expression. p-value was considered significant when it is less than 0.05.
Results:
A total of one hundred and three FFPE sporadic breast cancer samples were included in this study. The clinicopathological details of the studied samples including the age, cancer type, cancer grade, lymph node metastasis, and IHC of ER, PR, HER2, P53 and RAD51 are described in (Table 1). A total of sixty blood samples and twenty normal breast tissue from normal Saudi females with no personal history of breast cancer were included as a control group (Table 2).
The expression of RAD51 was investigated using immunohistochemistry approach and revealed a cytoplasmic stain in 58/103 (56%) of breast cancer cases studied (Figure 1). The frequency of G135C and C135C variants was 63/103 (61%)  and 11/80 (14%) in the tumor cells and control group respectively, while the frequency of the T172T, G172T variants was 57/103(55.3%) and 35/80 (44%) in tumor cells and control samples respectively (Table 1). Statistical analysis demonstrated a significant correlation between the incidence of RAD51 gene variants, G135C (P < 0.0001) and G172T (P < 0.0001) in the studied samples of breast cancer and the control group (Table 2). 
Table 3 presents the status of ER, PR, HER2, P53, and RAD51 of breast cancer patients investigated in this study. The genotype variants of RAD51 were calculated in the groups, and the results were compared. There was no significant difference in the polymorphic variant (G135C) of the RAD51 gene and the status of tumor grade, lymph node involvement, metastasis, ER, PR, HER2, and P53. On the other hand, the G172T variant revealed a statistically significant correlation only with ER expression (P=0.0001). Of 58 tumor samples expressed cytoplasmic stain for RAD51, 50 (86%) tumor cases demonstrated the G135C, C135C variants, while the frequency of T172T, G172T variants in the tumor samples that expressed cytoplasmic RAD51 was 30 (52%). The cytoplasm expression of RAD51 was compared with various pathological parameters and showed a statistically significant correlation only with p53 (P=0.0182) and the variants G135C, C135C (P=0.0001) but not with T172T, G172T genotypes (P=0.43) (Table 4).
Triple-negative breast cancer (TNBC) cases were significantly associated with the G135C variants (P=0.01) but no significant correlation was shown with the G172T variant (P=0.66). In the 26 TNBC cases, 21/26 (81%), 5/26 (19%) have G135C/C135C and G135G variants, respectively while, 12/26 (46%), 14/26 (54%) demonstrated T172T/G172T and G172G polymorphisms, respectively. Out of 26 of the TNBC cases, 18 (69%) cases showed overexpression of the cytoplasmic RAD51. Interestingly, 18/19 (95%) of the TNBC cases that overexpress RAD51 harbored G135C or C135C genotypes (Table 5).

Discussion:
Homologous recombination is involved in many aspects of genome maintenance such as repair of DNA lesions including DSB which provides essential support for DNA replication and meiotic chromosomal segregation. RAD51, a key protein in homologous recombination, plays a central role in genome stability by promoting homologous pairing and strands exchange  ADDIN EN.CITE [, ]. RAD51 expression is firmly regulated in normal cells to maintain chromosomal integrity [, ].  On the other hand, RAD51 overexpression has been positively correlated with breast cancer and other types of cancer  ADDIN EN.CITE []. The mechanism underlying the expression of RAD51 remains not fully understood. However, the functional studies proposed a regulatory role of the polymorphic variations in the 5’-UTR regions. For instance, Christopher et al. demonstrated a positive regulatory impact of the Early Growth Response 1 (EGR1) on the RAD51 expression in vitro. Besides, they proposed that the RAD51 promoter is gradually regulated during the metastasis process  []. In another functional study, the substitution of G allele with C allele at 135 loci and G with T at 172 loci showed enhancement in the RAD51 gene expression [].
In this study, we revealed that RAD51 G135C and G172T polymorphism were significantly associated with the risk of developing sporadic breast cancer. The polymorphisms of the 5’-UTR-RAD51 probably affect the stability of mRNA-RAD51, leading to overexpression of RAD51 and hence increase the risk of developing breast cancer. The expression of RAD51 was mainly cytoplasmic and it varies among breast cancer biomarkers like ER, PR, HER2 as well as polymorphic variants of the RAD51 promoter region. In particular, the cytoplasmic overexpression of RAD51 was significantly associated with the G135C, C135C variants, which is consistent with other studies that explained the promoter activation of the RAD51 gene in patients with the G135C, C135C variants [, ]. On the other hand, no significant correlation was detected between the T172T, T172G variants and the expression RAD51 []. In addition and consistent with other studies, our results indicated a significant association between the cytoplasmic expression of RAD51 and the occurrence of sporadic breast cancer and TNBC  ADDIN EN.CITE [, ]. Interestingly, this significant association increased when the RAD51 harbor the G135C variants. The G135C polymorphism might affect the mRNA splicing and or BRCA2 methylation(hypermethylation) that in turn increases the RAD51 protein expression. These findings suggest a potential role of RAD51 gene variants at the 5’-UTR and the hormonal receptor status in the regulation of the RAD51 expression. 
The carcinogenesis consequences of RAD51 overexpression have been explained by the role of RAD51 in the selection of tumor cells that harbor an efficient mechanism of DNA damage resistance [, ]. This assumption was supported by the findings of higher expression of RAD51 in p53 negative cells as the wild type of p53 represses the transcriptions of RAD51 and downregulates its expression   ADDIN EN.CITE [, , ]. Moreover, RAD51 overexpression has been reported to be associated with drug resistance since it is involved in genomic instability and DNA damage resistance behavior [].  Drug resistance was reported to be overcome by the down-regulation of RAD51 []. Another report displayed an enhancement of chemotherapies and /or ionizing radiation activity after targeting RAD51   ADDIN EN.CITE [, ]. Chemotherapy is the treatment of choice for TNBC; however, the significant improvement is limited due to the development of drug resistance. Since the overexpression of RAD51 is significantly associated with TNBC, RAD51 could be a potential therapeutic target for the treatment of TNBC cases. Recently, Jung Ok Lee (​https:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​?term=Lee%20JO%5BAuthor%5D&cauthor=true&cauthor_uid=31640742​) et al. demonstrated that the combination of cisplatin and metformin enhance the anticancer effect of cisplatin on human TNBC cells as metformin increase RAD51 degradation by ubiquitination [].
RAD51 expression is regulated by many factors that control the promoter region. P53 is one of the factors that downregulates the expression of RAD51 by interacting with its promoter region  ADDIN EN.CITE [, , ]. Additionally, Early Growth Response 1 (EGR1) binding site was reported as a regulatory site of the RAD51 gene expression []. Therefore, we believe that the 5'-UTR region plays an important role in the regulation of RAD51 expression and has an impact on the upstream and/ or downstream pathways of breast carcinogenesis.   
Collectively, our findings are supporting the molecular role of the 5’-UTR regions in RAD51 expression and underscoring the importance of RAD51 in the development of breast cancer, particularly TNBC. These findings support previous reports that have found an association between RAD51 overexpression and breast cancer grades [] and TNBC metastasis []. 
In conclusion, the current cohort confers the association between the polymorphic variation in the 5’-UTR regions of the RAD51 gene and the expression of RAD51 in breast cancer tissues. Moreover, RAD51 was significantly overexpressed in TNBC cases. And the C135 allele is strongly associated with the development of breast cancer. 
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Figures Legends:





Table 1: Clinical and pathological characteristics of paraffin-embedded samples of breast cancer.

Table 2: Percentage distribution of RAD51 gene polymorphism of breast cancer and control samples

Table 3: Relationship between the genotypes of RAD51 and pathological parameters.


Table 4: Relationship between the RAD51 expression and pathological parameters.
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Table 5: Percentage distribution of RAD51 gene polymorphism and RAD51 protein-expression of TNBC cases. 




